2Soliris – Price: $409.500
aHUS is a rare disease that causes systemic, complement-mediated thrombotic microangiopathy (TMA) that can lead to sudden, fatal complications and progressive failure of vital organs, including the kidney, heart, and brain.
In 2007, Alexion Pharmaceuticals launched Soliris, the first approved treatment for this life-threatening syndrome.
Soliris helps reduce symptoms such as blood clots, pain, difficulty breathing and headaches, as well as helping the patient survive as long as possible.
This drug treatment has an estimated cost of $409.500 per year.
